Last reviewed · How we verify
Routine vaccines
Routine vaccines stimulate the body's immune system to produce a specific immune response against infectious diseases.
At a glance
| Generic name | Routine vaccines |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Phase | Phase 3 |
Mechanism of action
This is achieved through the introduction of inactivated or weakened pathogens, which triggers the production of antibodies and immune cells that can recognize and fight the disease-causing agent. The immune response is then boosted by the body's natural defense mechanisms, providing long-term protection against future infections.
Approved indications
Common side effects
Key clinical trials
- HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer (EARLY_PHASE1)
- Increasing Measles Vaccination Coverage Through Supplementation With an SQ-LNS Incentive in Children Aged 6-23 Months (NA)
- Zoster Vaccine to Enhance Protection Against Zoster in Solid-organ Transplantation (PHASE2)
- A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab
- Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age (PHASE3)
- Mhealth Supported Bundle to Improve Vaccination Completion (NA)
- The Effect on Overall Mortality of a National Policy of Limiting Measles Vaccination to Children Below 12 Months of Age (PHASE4)
- Clinical Laboratory Evaluation, Assessment of Symptoms and Recovery in Patients With Post-COVID-19-Vaccination Syndrome
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Routine vaccines CI brief — competitive landscape report
- Routine vaccines updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI